Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Clinical trial NCT04082364 · COMPLETED

Trial details

NCT number: NCT04082364
Sponsor: MacroGenics
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Gastric Cancer Gastroesophageal Junction Cancer HER2-positive Gastric Cancer

Start date: 2019-09-30
Primary completion: 2024-01-15
Enrollment: 82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.